Media Coverage Of Omkar Speciality Chemicals Ltd.

Omkar Speciality inks pact with LASA Lab Media Coverage of our company in The myiris (12/04/2012)

Omkar Speciality Chemicals announced that the company has forayed into pharmaceutical business with its recent acquisition of LASA Laboratory located at Mahad in Raigad district, which has been an established player in the anthelmintic/ veterinary API segment with state-of-the--art API manufacturing facility.

The above acquisition will enable the company to focus on manufacturing anthelmintics, such as Albendazol EP, Albendazole IP/USP, cyromazine, Fenbendazole, BP VET/EP, Nitroxnil BP Vet, Ricobendazole, Toldimphos Sodium and Triclabendazole.

The API devision already in operation, and will initially focus on continuing the existing API business of LASA Laboratory, which has massive demand in India and abroad. The products are used as anthelmintics or deworming agents for venterinary. Currently the product portfolio in this division comprise 10 ingredients.

In addition, Omkar Speciality Chemicals has also plans to manufacture APIs with forword integration of some of the key intermediates which are currently being manufactures in Omkar Speciality Chemicals.

This acquisition is strategic for the company in terms of addition of new verticals as well as value addition.

Shares of the company gained Rs 4.15, or 7.11%, to settle at Rs 62.55. The total volume of shares traded was 83,618 at the BSE (Monday).